Shinichi Tamura’s experiment with putting a Westerner at the helm of Sosei in a bid to make the Japanese pharma company a more global operation has come to a close. Tamura — who founded the company — is now reclaiming the helm he handed to Peter Bains after limiting himself to the chairman’s position.
Sosei, which acquired UK-based Heptares’ GPCR platform in a $400 million deal back in 2015, isn’t backing away from the move to go global. Tamura says he is still intent on that strategy, with new investments being planned in R&D.
Bains, a 23-year GSK veteran, is giving up all his roles in the company, including his board position, as Sosei returns to the hands of a Japanese manager.
Japan’s pharma companies have all followed the road to international markets over the past decade, intent on extending their wings beyond the Japanese market in order to grow. But they all have their own way of doing that.
Bains became CEO of Sosei a couple of years after Christophe Weber — another GSK vet — landed the top job at Takeda, where the road to an international position led to its $62 billion acquisition of Shire, now set to close in early January.
Bains, though, is scheduled to depart at the end of this month.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 44,900+ biopharma pros who read Endpoints News by email every day.Free Subscription